 MINNEAPOLIS, Jan. 08, 2021 GLOBE NEWSWIRE -- Predictive Oncology Inc. NASDAQ: POAI Predictive Oncology or the Company, a knowledge-driven company focused on applying artificial intelligence AI to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 3,650,840 shares of its common stock, at a purchase price of 0.842 per share, for gross proceeds of approximately 3.0 million in a registered direct offering priced at-the-market under Nasdaq rules. Predictive Oncology has also agreed to issue to the investors unregistered warrants to purchase an aggregate of up to 1,825,420 shares of common stock. The closing of the offering is expected to occur on or about January 12, 2021, subject to the satisfaction of customary closing conditions. 